key: cord-0065224-21gb2rbp
authors: Franco, Eduardo L.; Shinder, Gayle A.; Volesky, Karena D.; Shapiro, Samantha B.; MacCosham, Aaron
title: Lessons from an unparalleled disruption to cancer prevention and control
date: 2021-06-30
journal: Prev Med
DOI: 10.1016/j.ypmed.2021.106686
sha: b0b87d5f5d3d249903ac7dff8c59eef52de403ea
doc_id: 65224
cord_uid: 21gb2rbp

nan

Lessons from an unparalleled disruption to cancer prevention and control

The measures taken in response to the coronavirus disease 2019 pandemic caused an extraordinary disruption to the entire range of cancer control activities, from prevention to care. Understandably, controlling the epidemic was a much greater and acute priority, which required the necessary personnel and material resources. Public health activities related to cancer screening and prevention, typically carried out in outpatient settings, were assigned a low priority and, in consequence, they were scaled back to conserve material and human resources, as well as to prevent exposure of cancer screening participants to SARS-CoV-2. Even services that were not completely interrupted saw marked reductions in attendance because of the widespread fear in the population regarding exposure risk. In addition, implementation of policy decisions intended to improve the uptake and quality of cancer screening services were delayed or suspended because the pandemic upended the process of evidence-based policymaking. Beginning in March 2020, public health systems everywhere co-opted epidemiologists, diagnosticians, cancer control managers, and health economists to respond to the formidable urgency of pandemic control.

We saw as our role in Preventive Medicine to provide our readers with a unique collection of articles on the impact of the pandemic on the spectrum of secondary prevention services targeted at cancers in anatomical sites for which screening is well established as opportunistic or organized programs, i.e., uterine cervix, breast, colon/rectum, and lung. We invited two leaders of the science and practice of cancer screening to serve as Guest Editors. Dr. Mona Saraiya is Team Lead, Epidemiology and Applied Research Branch, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, in Atlanta, Georgia. Dr. Linda Rabeneck is Vice-President for Prevention and Cancer Control, Ontario Health (Cancer Care Ontario), and Professor of Medicine, University of Toronto, in Ontario. Both are intimately involved with science, policymaking, and organizational structuring of cancer screening in their respective countries, the United States and Canada. They are also internationally respected thought leaders who regularly assist the World Health Organization and medical professional societies in screening guideline development. We gave Drs Saraiya and Rabeneck complete control in assembling an international team of experts in all aspects of cancer screening to contribute articles for a special issue on the impact of the COVID-19 pandemic on cancer screening. Planning began mid-July 2020, long before viable solutions were considered for the full resumption of screening programs.

As we have done with previous special issues, our Editorial Office in Montreal closely collaborated with the Guest Editors at all stages of production. We commissioned 19 articles by 146 contributing authors from 19 countries covering all continents, representing the best population-based evidence for the world experience with the disruptions in cancer screening. These articles described the lessons learned and provided thoughtful proposals not only for regaining lost ground but for redesigning cancer control systems to make them more resilient to future untoward situations. Drs Rabeneck's and Saraiya's insightful guest editorial for this special issue summarizes the diversity of experiences that different countries and healthcare systems had in facing the challenges imposed by the pandemic (Rabeneck and Saraiya, 2021) .

Of major importance to the effort of producing this collection of articles was the contribution of intellectual energy and time by the 44 reviewers who provided 73 in-depth and constructive anonymous critiques to assist authors to refine and enhance the value of their articles to our readership. Each of the 19 submissions was thoroughly peer reviewed by these generous reviewers, most of whom were themselves contributing authors to the special issue. We have used this approach in previous curated thematic collections in Preventive Medicine; the premise is that contributing authors are experts on the theme of the collection and wish to have their papers in good company in the journal issue. Therefore, it is in their best interest to assist their peers with insightful and helpful reviews for their companion papers. We extend our gratitude to the 44 reviewers by acknowledging their contributions in an honour's list at the end of this special issue.

We thank Drs Saraiya and Rabeneck for guest editing this special issue for Preventive Medicine. We are grateful to the 146 authors of this special issue's 19 papers for their valuable contributions and for working within the established timelines. We are particularly grateful to Elsevier's Post-Editorial Production Team in Chennai, India, led by Ms. V.S. Meenakkshi; they worked diligently to publish this issue while the pandemic ravaged India. Our thanks also go to those who stepped in to replace associates who had to be absent, such as Mr. Asogan Magendran, who led the final production effort. Our team is also indebted to our Publishing Liaison, Ms. Nicolette van Dijk, in Amsterdam, the Netherlands, who graciously permitted this special issue to be available with no paywall for six months following the release date. We trust that our readers engaged in the multiple fronts of cancer control will find this collection informative and providing foundational content for what comes next, i.e., the opportunity to recover what was lost and redesign the roadmap for improved and more resilient cancer screening for the next decades.

COVID-19 and the disruption of cancer screening programs: key lessons for the recovery

Contents lists available at ScienceDirect Preventive Medicine journal homepage: www